337 related articles for article (PubMed ID: 33654234)
1. Certain beta blockers (e.g., bisoprolol) may be reevaluated in hypertension guidelines for patients with left ventricular hypertrophy to diminish the ventricular arrhythmic risk.
Koracevic G; Stojanovic M; Lovic D; Zdravkovic M; Sakac D
J Hum Hypertens; 2021 Jul; 35(7):564-576. PubMed ID: 33654234
[TBL] [Abstract][Full Text] [Related]
2. A Discrepancy: Calcium Channel Blockers Are Effective for the Treatment of Hypertensive Left Ventricular Hypertrophy but Not as Effective for Prevention of Heart Failure.
Koracevic G; Perisic Z; Stanojkovic M; Stojanovic M; Zdravkovic M; Tomasevic M; Djordjevic D; Mladenovic K; Koracevic M; Trkulja J
Med Princ Pract; 2022; 31(5):454-462. PubMed ID: 36044874
[TBL] [Abstract][Full Text] [Related]
3. Significance of Beta-Blocker in Patients with Hypertensive Left Ventricular Hypertrophy and Myocardial Ischemia.
Koracevic G; Mićić S; Stojanovic M; Bozinovic N; Simic D; Lović D; Krstic N; Tomašević RJ
Curr Vasc Pharmacol; 2023; 21(2):81-90. PubMed ID: 36722475
[TBL] [Abstract][Full Text] [Related]
4. Beta-blockers in Hypertensive Left Ventricular Hypertrophy and Atrial Fibrillation Prevention.
Koraćević G; Mićić S; Stojanović M; Zdravkovic M; Simić D; Kostić T; Atanasković V; Janković-Tomašević R
Curr Vasc Pharmacol; 2024; 22(1):19-27. PubMed ID: 38031765
[TBL] [Abstract][Full Text] [Related]
5. Left ventricular hypertrophy and clinical outcomes in hypertensive patients.
Ruilope LM; Schmieder RE
Am J Hypertens; 2008 May; 21(5):500-8. PubMed ID: 18437140
[TBL] [Abstract][Full Text] [Related]
6. Antihypertensive therapy and sudden cardiac death, should we expect the unexpected?
Sanidas E; Malliaras K; Papadopoulos D; Velliou M; Tsakalis K; Zerva K; Barbetseas J
J Hum Hypertens; 2020 May; 34(5):339-345. PubMed ID: 31937855
[TBL] [Abstract][Full Text] [Related]
7. The Effect of Bisoprolol on Premature Ventricular Complex in Vietnamese Patients with Hypertension and Left Ventricular Hypertrophy.
Kim Tran S; Ngo TH; Phuong Nguyen AT; Ngoc Huynh HT; Vo CT; Bao Nguyen NN; Nguyen TH; Huynh MV
Curr Hypertens Rev; 2023; 19(1):42-51. PubMed ID: 36627790
[TBL] [Abstract][Full Text] [Related]
8. Treatment of left ventricular hypertrophy in hypertensive patients.
Tamargo J; Delpón E; Valenzuela C
Eur Heart J; 1993 Nov; 14 Suppl J():102-6. PubMed ID: 8281952
[TBL] [Abstract][Full Text] [Related]
9. Selection of antihypertensive therapy: cardiac and extracardiac considerations.
Messerli FH; Soria F
Cardiology; 1992; 81(4-5):316-24. PubMed ID: 1301259
[TBL] [Abstract][Full Text] [Related]
10. Hypertension, left ventricular hypertrophy, and sudden cardiac death.
Shenasa M; Shenasa H
Int J Cardiol; 2017 Jun; 237():60-63. PubMed ID: 28285801
[TBL] [Abstract][Full Text] [Related]
11. Electrophysiological and therapeutic implications of cardiac arrhythmias in hypertension.
Vester EG; Kuhls S; Ochiulet-Vester J; Vogt M; Strauer BE
Eur Heart J; 1992 Sep; 13 Suppl D():70-81. PubMed ID: 1396864
[TBL] [Abstract][Full Text] [Related]
12. Hypertension and sudden cardiac death.
Messerli FH
Am J Hypertens; 1999 Dec; 12(12 Pt 3):181S-188S. PubMed ID: 10619570
[TBL] [Abstract][Full Text] [Related]
13. Effects of antihypertensive agents on the left ventricle: clinical implications.
Díez J; González A; López B; Ravassa S; Fortuño MA
Am J Cardiovasc Drugs; 2001; 1(4):263-79. PubMed ID: 14728026
[TBL] [Abstract][Full Text] [Related]
14. Does the ADMA/DDAH/NO pathway modulate early regression of left ventricular hypertrophy with esmolol?
Quintana-Villamandos B; Delgado-Baeza E
Med Hypotheses; 2016 Feb; 87():44-7. PubMed ID: 26826640
[TBL] [Abstract][Full Text] [Related]
15. Real role of β-blockers in regression of left ventricular mass in hypertension patients: Bayesian network meta-analysis.
Xing F; Chen J; Zhao B; Jiang J; Tang A; Chen Y
Medicine (Baltimore); 2017 Mar; 96(10):e6290. PubMed ID: 28272254
[TBL] [Abstract][Full Text] [Related]
16. The importance of left ventricular hypertrophy in human hypertension.
Kahan T
J Hypertens Suppl; 1998 Sep; 16(7):S23-9. PubMed ID: 9855028
[TBL] [Abstract][Full Text] [Related]
17. Effects of ACE inhibition versus non-ACE inhibitor antihypertensive treatment on myocardial fibrosis in patients with arterial hypertension. Retrospective analysis of 120 patients with left ventricular endomyocardial biopsies.
Brilla CG; Rupp H; Maisch B
Herz; 2003 Dec; 28(8):744-53. PubMed ID: 14689110
[TBL] [Abstract][Full Text] [Related]
18. Angiotensin II receptor blockers and cardiovascular protection: focus on left ventricular hypertrophy regression and atrial fibrillation prevention.
Cuspidi C; Negri F; Zanchetti A
Vasc Health Risk Manag; 2008; 4(1):67-73. PubMed ID: 18629360
[TBL] [Abstract][Full Text] [Related]
19. Angiotensin converting enzyme inhibition and dihydropyridine calcium channel blockade in the treatment of left ventricular hypertrophy in arterial hypertension.
Palmieri V; Devereux RB
Minerva Cardioangiol; 2002 Jun; 50(3):169-74. PubMed ID: 12107398
[TBL] [Abstract][Full Text] [Related]
20. Comparative efficacy of different types of antihypertensive drugs in reversing left ventricular hypertrophy as determined with echocardiography in hypertensive patients: A network meta-analysis of randomized controlled trials.
Chen JS; Pei Y; Li CE; Li YN; Wang QY; Yu J
J Clin Hypertens (Greenwich); 2020 Dec; 22(12):2175-2183. PubMed ID: 33190366
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
